Protocol summary
-
Study aim
-
Improving the symptoms of PCOS and the results of ART with the help of resveratrol and using this supplement to manage the treatment of patients
-
Design
-
56 patients with polycystic ovary syndrome are included in the project. Patients are randomly divided into two groups: the group receives eight hundred milligrams of resveratrol per day, and the group receives two placebo capsules for 60 days.
-
Settings and conduct
-
Sampling of Omid fertility clinic
Performing experiments in the embryology laboratory of Tehran University of Medical Sciences
-
Participants/Inclusion and exclusion criteria
-
Patients with infertility caused by PCOS in the age range of 18-35 years. The diagnosis of PCOS will be based on the Rotterdam criteria and having at least two of the following three criteria: amenorrhea or oligomenorrhea, clinical/or biochemical signs of hyperandrogenism, polycystic ovary observation on ultrasound. (Ultrasound criterion for polycystic ovaries is the presence of at least 12 follicles with a diameter of 2 to 9 mm or an increase in ovarian volume of more than 10 cubic centimeters in the transvaginal ultrasound scan).
Exclusion criteria: include pregnancy, adrenal hyperplasia, androgen-secreting tumors, hyperprolactinemia, thyroid dysfunction, diabetes, or impaired glucose tolerance. Also, people who have used antioxidant supplements, ovulation-inducing drugs, or drugs affecting the hormonal profile 6 months before the start of the plan will not be included in the plan.
-
Intervention groups
-
Resveratrol drug user group
Placebo consumer group
-
Main outcome variables
-
Evaluation of Sirtuin1, PGC1-α, UCP2 proteins expression
Evaluation of PGC1-α, UCP2, Nrf1, TFAM gene expression
Evaluation of antioxidant genes
Assessment of intracellular ATP
Determining the number of mtDNA copies
Examination of TAC and TOS
Investigating the antioxidant markers of follicular fluid
Evaluation of ART results
General information
-
Reason for update
-
Due to the addition of the investigation of antioxidant genes and the investigation of antioxidant indicators in follicular fluid and granulosa cells, which are related to mitochondrial function, these items were added to the primary outcome variables. Examination of chemical and clinical pregnancy is also done, which was added in the secondary outcome variables section.
-
Acronym
-
PCOs
-
IRCT registration information
-
IRCT registration number:
IRCT20221106056417N1
Registration date:
2023-02-09, 1401/11/20
Registration timing:
prospective
Last update:
2024-10-02, 1403/07/11
Update count:
3
-
Registration date
-
2023-02-09, 1401/11/20
-
Registrant information
-
-
Recruitment status
-
Recruitment complete
-
Funding source
-
-
Expected recruitment start date
-
2023-04-21, 1402/02/01
-
Expected recruitment end date
-
2024-04-20, 1403/02/01
-
Actual recruitment start date
-
empty
-
Actual recruitment end date
-
empty
-
Trial completion date
-
empty
-
Scientific title
-
Investigating the effect of resveratrol administration on the expression of factors involved in mitochondrial function and biogenesis in granulosa cells of patients with PCOS who are candidates for ART: a three-blind randomized controlled clinical trial
-
Public title
-
Investigating the effect of resveratrol on polycystic ovary syndrome
-
Purpose
-
Health service research
-
Inclusion/Exclusion criteria
-
Inclusion criteria:
Diagnosis of Polycystic ovary syndrome (PCOS) based on Rotterdam criteria
Polycystic ovary syndrome (PCOS) patients who are candidates for ART
Exclusion criteria:
Pregnancy
Adrenal hyperplasia
Androgen-secreting tumors
Hyperprolactinemia
Thyroid dysfunction
Diabetes or impaired glucose tolerance
-
Age
-
From 18 years old to 35 years old
-
Gender
-
Female
-
Phase
-
3
-
Groups that have been masked
-
- Participant
- Investigator
- Data analyser
-
Sample size
-
Target sample size:
56
More than 1 sample in each individual
Number of samples in each individual:
2
Follicular fluid and granulosa cells
-
Randomization (investigator's opinion)
-
Randomized
-
Randomization description
-
Eligible patients after visiting the women's clinic respectively
will be included in the study randomly. Block randomization
It will be in such a way that within each floor, the method of blocks
is used interchangeably. Blocks are binary and include AB and BA
will be. The randomization tool will be a table of random numbers that will be used For the numbers 0 to 4 in the table of random numbers from the sequences A and B and for Numbers 5 to 9 are used from the sequence of B.A. It is necessary to mention the letter A
It means the intervention group and the letter B means the control group. Direction Concealment We use random allocation concealment to
The way that the assigned group is not known before assigning the individual. the door In this method, each random sequence is created on a card
It will be registered and the cards will be placed in sealed envelopes in order
They are placed. To preserve the random sequence, on
The outer surface of the envelopes is numbered in the same order.
Finally, the lid of the letter envelopes is glued and placed inside box respectively A is placed. At the time of starting the registration of participants, based on The order of entry of qualified participants into the study, one of the envelopes The letter is opened, and the assigned group of that participant is revealed.
-
Blinding (investigator's opinion)
-
Triple blinded
-
Blinding description
-
This study will be triple-blind and the patient, the researcher, and the statistical analyst
Patients do not have any information about the type of group therapy and the person who deciphers the code
It is outside the research team. The studied drug is resveratrol and placebo
In a completely similar shape and appearance, each with 60 pieces in a package
There are similar ones in the place of medicine based on random allocation to people
The study will be presented. It should be noted that the medicinal content of each
Which of the bottles was coded by a person outside the research package
The bottles are labeled and the research team is aware of their interpretation
do not have
-
Placebo
-
Used
-
Assignment
-
Parallel
-
Other design features
-
Ethics committees
1
-
Ethics committee
-
-
Approval date
-
2023-01-07, 1401/10/17
-
Ethics committee reference number
-
IR.TUMS.SHARIATI.REC.1401.021
Health conditions studied
1
-
Description of health condition studied
-
Polycystic ovary syndrome
-
ICD-10 code
-
E28.2
-
ICD-10 code description
-
Polycystic ovary syndrome
Primary outcomes
1
-
Description
-
Examining PGC1 alpha, Nrf1, TFAM, UCP2 genes expression
-
Timepoint
-
Sixty days after taking the medicine
-
Method of measurement
-
real time PCR
2
-
Description
-
Analysis of SIRT1, PGC1 alpha, UCP2 protein expression
-
Timepoint
-
Sixty days after taking the medicine
-
Method of measurement
-
Western Blot
3
-
Description
-
Analysis mtDNA
-
Timepoint
-
Sixty days after taking the medicine
-
Method of measurement
-
the quantitative real-time (q)PCR reactions
4
-
Description
-
total antioxidant capacity (TAC)
-
Timepoint
-
60 days after the start of the intervention, check the follicular fluid and granulosa cells
-
Method of measurement
-
ELIZA
5
-
Description
-
total oxidant statues (TOS)
-
Timepoint
-
60 days after the start of the intervention, check on follicular fluid and granulosa cells
-
Method of measurement
-
ELIZA
6
-
Description
-
Examination of antioxidant genes
-
Timepoint
-
Sixty days after taking the medicine
-
Method of measurement
-
real time PCR
7
-
Description
-
Examining the content of intracellular ATP
-
Timepoint
-
Sixty days after taking the medicine
-
Method of measurement
-
ELIZA
8
-
Description
-
Examination of the oxidative stress index (OSI) (OSI)
-
Timepoint
-
Sixty days after taking the medicine
-
Method of measurement
-
determined by dividing TOS by TAC
9
-
Description
-
Investigating the antioxidant markers of follicular fluid
-
Timepoint
-
Sixty days after taking the medicine
-
Method of measurement
-
ELIZA
Secondary outcomes
1
-
Description
-
The number and quality of oocytes
-
Timepoint
-
60 days after the start of the intervention
-
Method of measurement
-
Counting, optical microscopy
2
-
Description
-
Number and quality of embryos
-
Timepoint
-
60 days after the start of the intervention
-
Method of measurement
-
Counting, optical microscopy
3
-
Description
-
Chemical pregnancy
-
Timepoint
-
16 days after embryo transfer
-
Method of measurement
-
hCG blood tests
4
-
Description
-
Clinical pregnancy
-
Timepoint
-
around 7 weeks of gestation
-
Method of measurement
-
the presence of a gestational sac, fetal heartbeat observed at ultrasound scan
Intervention groups
1
-
Description
-
Intervention group: use of resveratrol. In this group of patients, for 60 days until puncture, they take two capsules of 800 mg of resveratrol daily, twice in the morning and in the evening. Their routine treatment, including metformin, is not stopped.
-
Category
-
Treatment - Drugs
1
-
Sponsor
-
-
Grant name
-
-
Grant code / Reference number
-
-
Is the source of funding the same sponsor organization/entity?
-
Yes
-
Title of funding source
-
Tehran University of Medical Sciences
-
Proportion provided by this source
-
100
-
Public or private sector
-
Public
-
Domestic or foreign origin
-
Domestic
-
Category of foreign source of funding
-
empty
-
Country of origin
-
-
Type of organization providing the funding
-
Academic
Sharing plan
-
Deidentified Individual Participant Data Set (IPD)
-
Yes - There is a plan to make this available
-
Study Protocol
-
Yes - There is a plan to make this available
-
Statistical Analysis Plan
-
Undecided - It is not yet known if there will be a plan to make this available
-
Informed Consent Form
-
Undecided - It is not yet known if there will be a plan to make this available
-
Clinical Study Report
-
Yes - There is a plan to make this available
-
Analytic Code
-
Undecided - It is not yet known if there will be a plan to make this available
-
Data Dictionary
-
Undecided - It is not yet known if there will be a plan to make this available
-
Title and more details about the data/document
-
All the data obtained in the research will be published in one of the relevant scientific journals.
-
When the data will become available and for how long
-
Beginning of access spring 1403
-
To whom data/document is available
-
Researchers working in academic institutions
-
Under which criteria data/document could be used
-
The data of this research can be used as an adjuvant treatment method in patients with polycystic ovary syndrome undergoing IVF/ICSI.
-
From where data/document is obtainable
-
Negar Ajabi Ardeh jani
-
What processes are involved for a request to access data/document
-
By sending an email to the corresponding author.
-
Comments
-